Asset Details
Do you wish to reserve the book?
Trial of SAGE-217 in Patients with Major Depressive Disorder
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Trial of SAGE-217 in Patients with Major Depressive Disorder
Do you wish to request the book?
Trial of SAGE-217 in Patients with Major Depressive Disorder
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Trial of SAGE-217 in Patients with Major Depressive Disorder
2019
Overview
Patients with major depression were treated with an oral γ-aminobutyric acid type A–receptor modulator for 14 days. At day 15, patients who received the drug had a greater reduction in depressive symptoms than patients who received placebo. Headache was the most common adverse event.
Publisher
Massachusetts Medical Society
Subject
/ Adult
/ Antidepressive Agents - adverse effects
/ Antidepressive Agents - therapeutic use
/ Anxiety
/ Depressive Disorder, Major - classification
/ Depressive Disorder, Major - drug therapy
/ Dizziness - chemically induced
/ Female
/ GABA Modulators - adverse effects
/ GABA Modulators - therapeutic use
/ Headache
/ Humans
/ Male
/ Nausea
/ Patients
